Clinical trials
Phase 2 Colitis, Ulcerative trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
142 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 3 |
| 2003 | 2 |
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 4 |
| 2009 | 2 |
| 2010 | 3 |
| 2011 | 6 |
| 2012 | 7 |
| 2013 | 6 |
| 2014 | 1 |
| 2015 | 4 |
| 2016 | 8 |
| 2017 | 4 |
| 2018 | 9 |
| 2019 | 11 |
| 2020 | 8 |
| 2021 | 11 |
| 2022 | 11 |
| 2023 | 10 |
| 2024 | 7 |
| 2025 | 10 |
| 2026 | 12 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 63 |
| Terminated | 30 |
| Recruiting | 22 |
| Active, not recruiting | 17 |
| Withdrawn | 5 |
| Unknown status | 4 |
| Enrolling by invitation | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Pfizer | 8 |
| Sanofi | 7 |
| Eli Lilly and Company | 6 |
| Genentech, Inc. | 6 |
| AbbVie | 5 |
| Bristol-Myers Squibb | 5 |
| Janssen Research & Development, LLC | 5 |
| Amgen | 4 |
| Takeda | 4 |
| Brigham and Women's Hospital | 3 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Colitis, Ulcerative | 142 |
| Inflammatory Bowel Diseases | 28 |
| Crohn Disease | 16 |
| Colitis | 12 |
| Ulcer | 5 |
| Gastrointestinal Diseases | 4 |
| Lymphoma, Follicular | 4 |
| Autoimmune Diseases | 2 |
| Colonic Diseases | 2 |
| Digestive System Diseases | 2 |
Trials
Showing 1 to 25 of 142. Each trial links to its page on Pharma Observatory.
42 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.